BB Biotech reported a challenging Q1/25, reflecting heightened volatility across global financial markets and uncertainty in healthcare policies. The company posted a Q1 net loss of CHF 241 million. The shares closed at a 12.7% discount to Net Asset Value (NAV) on 7 July, well below their five-year average premium of 7.7%.
LÄS MER
